GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

This has lagged the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08% in that time. Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches boosting long-term growth.

Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

exceeding the Medical sector's loss of 5.3% and the S&P 500's loss of 2.2%. The investment community will be paying close attention to the earnings performance of Eli Lilly in its upcoming release.

and delivering life-changing medicines to address some of the world's most pressing medical needs. With a market cap of $759.4 billion, Eli Lilly operates across diverse therapeutic areas ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

Eli Lilly is seeking to end a lawsuit filed by ... And in the nearly two years that tirzepatide was in shortage, telehealth companies, medical spas and other clients of compounding pharmacies ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular ...